|D019966||Substance-Related Disorders NIH||0.50|
There is one clinical trial.
The purpose of this study is to test the efficacy of a substance use disorder intervention delivered via a mobile application in an adult population during the COVID-19 pandemic. This study that will test the comparative efficacy of the mobile-app based substance use disorder program to reduce substance use relative to a wait list control condition, and explore between group differences on quality of life indices as well as retention and engagement during COVID-19.
Description: Range from 0-100 (no pain to worst pain imaginable)Measure: Pain rating Time: Difference between baseline and post-treatment (8 weeks from baseline)
Description: Total score between 0-27, higher scores indicate greater levels of depressionMeasure: Patient Health Questionnaire-9 (PHQ-9) Time: Difference between baseline and post-treatment (8 weeks from baseline)
Description: Total score between 0-21, higher scores indicate greater levels of anxietyMeasure: General Anxiety Disorder-7 (GAD-7) Time: Difference between baseline and post-treatment (8 weeks from baseline)
Description: Range from 8 to 32, with higher values indicating higher satisfactionMeasure: Client Satisfaction Questionnaire (CSQ) Time: Post-treatment (8 weeks from baseline)
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports